Just as investors were hoping for ImmunityBio (IBRX) to build on its momentum in the cancer drug market, the U.S. Food and Drug Administration (FDA) threw a wrench into the works. A sharply worded warning letter from the regulator sent the biotech’s stock tumbling more than 3% during Monday’s trading session.
The trigger? Not the safety or efficacy of the company’s drug, but how ImmunityBio chose to talk about it.
In a warning letter dated mid-March, the FDA took issue with promotional materials ImmunityBio had created for its cancer immunotherapy Anktiva. The agency deemed the materials “false or misleading.” Specifically, the letter targeted two channels:
The irony is hard to miss. The FDA approved Anktiva nearly two years ago for the treatment of adults with BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Far from “blocking” the drug, the agency had already opened the door to the market.
Faced with the FDA’s tough stance, ImmunityBio quickly struck a conciliatory tone. On Monday, the company said it had filed a formal response to the warning letter. It emphasized that:
On the surface, this looks like a swift crisis-management move. But in the eyes of investors, the response only highlighted bigger problems.
The 3%+ drop in share price reflects two key concerns among investors:
First, the company came across as reckless and sensationalistic. For an already approved drug to be promoted under a headline suggesting the FDA is blocking lifesaving treatments — that looks less like science and more like emotional hype. It erodes the company’s scientific credibility.
Second, the retreat felt weak and wasteful. The moment the FDA pushed back, ImmunityBio pulled everything — even asking third-party platforms to delete the podcast. This zero-resistance posture makes the entire promotional campaign look like a rushed, compliance-lacking misstep. Precious company time and resources were burned on a short-lived, ill-considered marketing push.
Every biotech management team makes mistakes. But ImmunityBio has just stepped into a minefield that the pharmaceutical industry knows all too well: using emotional, misleading language to describe an already approved drug.
In the short term, a 3% decline is hardly a disaster. The bigger lesson is this: for a product that only recently won FDA approval, regulatory trust is a hard-won asset. Once a company is seen as pushing the envelope on promotion, every future marketing move will be scrutinized under a microscope.
Investors don’t necessarily need to abandon ImmunityBio entirely. But they should start paying close attention to whether the company can keep its messaging in check going forward.
